Gyre Therapeutics (GYRE) Long-Term Deferred Tax (2022 - 2026)

Gyre Therapeutics (GYRE) has 5 years of Long-Term Deferred Tax data on file, last reported at $7.7 million in Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $7.7 million, up 32.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.7 million (up 32.74% YoY), and the FY2025 annual result was $6.9 million, up 22.32% from the prior year.
• Long-Term Deferred Tax advanced to $7.7 million in Q1 2026 per GYRE's latest filing, from $6.9 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $7.7 million in Q1 2026 and troughed at $4.1 million in Q4 2022.
• A 5-year average of $5.7 million and a median of $5.6 million in 2024 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2023 and 2026: Long-Term Deferred Tax climbed 15.05% in 2023, then surged 32.74% in 2026.
• A 5-year view of Long-Term Deferred Tax shows it stood at $4.1 million in 2022, then increased by 15.05% to $4.7 million in 2023, then advanced by 19.68% to $5.6 million in 2024, then advanced by 22.32% to $6.9 million in 2025, then increased by 12.37% to $7.7 million in 2026.
• Business Quant data shows GYRE's Long-Term Deferred Tax at $7.7 million in Q1 2026, $6.9 million in Q4 2025, and $6.7 million in Q3 2025.